Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.

Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K, Gravis G, James ND, Liu G, Matheson D, Murphy L, Oldroyd RE, Parmar MKB, Rogozinska E, Sfumato P, Sweeney CJ, Sydes MR, Tombal B, White IR, Tierney JF, STOPCAP Collaboration

Open source

DOI: 10.1016/s1470-2045(23)00230-9
Published: 2023 Jul
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-23-00230-9,
  title = {Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.},
  author = {Vale CL and Fisher DJ and Godolphin PJ and Rydzewska LH and Boher JM and Burdett S and Chen YH and Clarke NW and Fizazi K and Gravis G and James ND and Liu G and Matheson D and Murphy L and Oldroyd RE and Parmar MKB and Rogozinska E and Sfumato P and Sweeney CJ and Sydes MR and Tombal B and White IR and Tierney JF and STOPCAP Collaboration},
  year = {2023},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(23)00230-9},
  url = {https://doi.org/10.1016/s1470-2045(23)00230-9}
}

RIS

TY  - JOUR
TI  - Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
AU  - Vale CL
AU  - Fisher DJ
AU  - Godolphin PJ
AU  - Rydzewska LH
AU  - Boher JM
AU  - Burdett S
AU  - Chen YH
AU  - Clarke NW
AU  - Fizazi K
AU  - Gravis G
AU  - James ND
AU  - Liu G
AU  - Matheson D
AU  - Murphy L
AU  - Oldroyd RE
AU  - Parmar MKB
AU  - Rogozinska E
AU  - Sfumato P
AU  - Sweeney CJ
AU  - Sydes MR
AU  - Tombal B
AU  - White IR
AU  - Tierney JF
AU  - STOPCAP Collaboration
PY  - 2023
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(23)00230-9
UR  - https://doi.org/10.1016/s1470-2045(23)00230-9
ER  -

APA

CL, V., DJ, F., PJ, G., LH, R., JM, B., S, B., YH, C., NW, C., K, F., G, G., ND, J., G, L., D, M., L, M., RE, O., MKB, P., E, R., P, S., CJ, S., MR, S., B, T., IR, W., JF, T., & Collaboration, S. (2023). Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(23)00230-9

Source records

pubmed · retrieved 2026-09-27T15:59:29.054Z